Circulating Hsp90 Isoform Levels in Overweight and Obese Children and the Relation to Nonalcoholic Fatty Liver Disease: Results from a Cross-Sectional Study

Balanescu, A.; Stan, Iustina Violeta; Codreanu, Ioana Florentina; Comanici, Valentina Daniela; Bălănescu, Eugenia; Bălănescu, Paul

doi:10.1155/2019/9560247

Cited by 19 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings of our literature survey confirmed the implication of the following: HSP90AB1 has been suggested as a possible biomarker in overweight and obese children with NAFLD [41]; HLA-B [42], CTNNB1 [43] and HSPA5 [44] are found to be abnormally expressed in NAFLD patients; CDKN1A polymorphism is associated with the development of human NAFLD [45]; TRAF1 has been also detected in NAFLD patients [46]; HSPB1 phosphorylation site has been differed between NAFLD cohorts [47]; SMAD4 was overexpresed in NASH patients [48]; SMAD2/3 phosphorylation and nuclear translocation documented in the liver of NASH patients [49]; RELA is well-known to cause inflammatory responses in NAFLD [50]; PIK3R3 has been proposed as an effective candidate target for the development of NAFLD [51]; GSK3B inhibition has been proposed as a possible therapeutic target to manipulate the NAFLD [52].…”

Section: Thsupporting

confidence: 84%

Construction and Analysis of Protein-Protein Interaction Network of Non-Alcoholic Fatty Liver Disease

Amanatidou

Dedoussis

2020

Preprint

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a disease with multidimensional complexities. Many attempts have been made over the years to treat this disease but its incidence is rising. For this reason, the need to identify and study new candidate NAFLD biomarkers is of utmost importance. Systems-based approaches such as the analysis of protein-protein interaction (PPI) network could lead to the discovery of new disease biomarkers that can then be translated into clinical practice. The aim of this study is to analyze the interaction network of human proteins associated with NAFLD as well as their experimentally verified interactors and to propose new candidate proteins that may be involved in this disease. Computational analysis made it feasible to detect 77 candidate proteins associated with NAFLD, having high network scores. Furthemore, clustering analysis was performed to identify densely connected regions with biological significance in this network. Additionally, gene expression analysis was conducted to validate part of the findings of this research work. We believe that our research will be helpful in extending experimental efforts to address the pathogenesis and progression of NAFLD.

show abstract

Section: Thsupporting

confidence: 84%

Construction and Analysis of Protein-Protein Interaction Network of Non-Alcoholic Fatty Liver Disease

Amanatidou

Dedoussis

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Anthropometric assessment results and patients' characteristics are described in Tables 1 and 2, respectively. Study population characteristics were also fully described in a previously published study based on the MR-PONy cohort [12,13].…”

Section: Resultsmentioning

confidence: 99%

“…We conducted a cross-sectional study on 68 consecutive pediatric patients admitted in a single center (Pediatric Clinic of the National Institute for Mother and Child Health "Alessandrescu-Rusescu," Bucharest) in a one-year period (January to December 2017). Those patients were part of the MR-PONy cohort (Metabolic and cardiovascular Risk factors in a Pediatric Overweight and obese population with or without NAFLD) whose characteristics were previously fully described in our previous studies [12,13]. All eligible patients had not been treated prior to enrollment.…”

Section: Methodsmentioning

confidence: 99%

Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study

Balanescu

Codreanu

Comanici

et al. 2020

BioMed Research International

Self Cite

View full text Add to dashboard Cite

The aim of the study was to evaluate serum Endocan and Lumican levels as biomarkers for pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and to explore their associations with pediatric cardiometabolic risk factors. We conducted a cross-sectional study on 68 pediatric obese and overweight (O&O) patients. Ten healthy controls were recruited. Serum Lumican and Endocan levels were analyzed using ELISA kits. O&O patients had lower levels of Endocan compared to healthy controls (p<0.001). There were no differences between serum Endocan levels in O&O patients with NAFLD and those without (p=0.53). Patients considered having Nonalcoholic Steatohepatitis (NASH) had lower Endocan levels compared to O&O patients without NASH (p=0.026). Patients with metabolic syndrome had lower levels of Endocan (p=0.003). There were no significant differences between serum Lumican levels in O&O children compared to healthy controls. Lumican levels were higher in patients with hypertension (p=0.04). In O&O patients, Lumican levels were negatively correlated with Endocan levels (r=−0.37, p=0.002). Endocan seems a promising biomarker for the evaluation of pediatric NASH. Lumican was not confirmed as a biomarker for NAFLD in our cohort but was associated with higher arterial pressure. Low Endocan levels are accompanied by high serum Lumican levels, and this could be an early signature of cardiometabolic risk.

show abstract

“…Thus, targeting Hsp90β might help to regulate the blood sugar of patients with type 2 diabetes. In patients with nonalcoholic fatty liver disease (NAFLD), the Hsp90β levels in serum was found to be very high [ 93 ]. Balanescu and colleagues conducted a study on overweight and obese children and found serum Hsp90β, but not Hsp90α, to be significantly higher.…”

Section: Cytosolic Hsp90mentioning

confidence: 99%

Cytosolic Hsp90 Isoform-Specific Functions and Clinical Significance

Maiti

Picard

2022

Biomolecules

View full text Add to dashboard Cite

The heat shock protein 90 (Hsp90) is a molecular chaperone and a key regulator of proteostasis under both physiological and stress conditions. In mammals, there are two cytosolic Hsp90 isoforms: Hsp90α and Hsp90β. These two isoforms are 85% identical and encoded by two different genes. Hsp90β is constitutively expressed and essential for early mouse development, while Hsp90α is stress-inducible and not necessary for survivability. These two isoforms are known to have largely overlapping functions and to interact with a large fraction of the proteome. To what extent there are isoform-specific functions at the protein level has only relatively recently begun to emerge. There are studies indicating that one isoform is more involved in the functionality of a specific tissue or cell type. Moreover, in many diseases, functionally altered cells appear to be more dependent on one particular isoform. This leaves space for designing therapeutic strategies in an isoform-specific way, which may overcome the unfavorable outcome of pan-Hsp90 inhibition encountered in previous clinical trials. For this to succeed, isoform-specific functions must be understood in more detail. In this review, we summarize the available information on isoform-specific functions of mammalian Hsp90 and connect it to possible clinical applications.

show abstract

Circulating Hsp90 Isoform Levels in Overweight and Obese Children and the Relation to Nonalcoholic Fatty Liver Disease: Results from a Cross-Sectional Study

Cited by 19 publications

References 23 publications

Construction and Analysis of Protein-Protein Interaction Network of Non-Alcoholic Fatty Liver Disease

Construction and Analysis of Protein-Protein Interaction Network of Non-Alcoholic Fatty Liver Disease

Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study

Cytosolic Hsp90 Isoform-Specific Functions and Clinical Significance

Contact Info

Product

Resources

About